Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 4,369.00
+73.00 (1.70%)
Oct 27, 2025, 3:30 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.11T JPY in the quarter ending June 30, 2025, a decrease of -8.39%. This brings the company's revenue in the last twelve months to 4.48T, up 1.52% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.48T
Revenue Growth
+1.52%
P/S Ratio
1.50
Revenue / Employee
94.41M
Employees
47,455
Market Cap
6.71T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.40T |
| Astellas Pharma | 1.94T |
| Daiichi Sankyo Company | 1.92T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.04T |
| Olympus | 969.02B |
| HOYA Corporation | 876.09B |
| Eisai | 803.02B |
Takeda Pharmaceutical Company News
- 4 days ago - Takeda Pharmaceutical Company Limited (TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules Transcript - Seeking Alpha
- 4 days ago - Takeda Pharmaceutical Company Limited (TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules - Slideshow - Seeking Alpha
- 5 days ago - China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion - WSJ
- 5 days ago - China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda - Reuters
- 5 days ago - Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market - PRNewsWire
- 5 days ago - Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Business Wire
- 12 days ago - Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact - Benzinga
- 12 days ago - US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership - Reuters